glp 1 agonists tirzepatide Bridging the gap between GLP1-receptor and cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology The dual agonist action of
Description
Hope DCD, Hinds CE, Lopes T, Vincent ML, Shrewsbury JV, Yu ATC, et al
The ability to have medications delivered directly to their doorsteps, often with the option of automatic refills, appeals to many patients and contributes to the growth of this segment

Rosenbaum, M., and Leibel, R

A systematic review of the effect of semaglutide on lean mass: insights from clinical trials

The CV safety of a lower dose of liraglutide (1.8 mg, Victoza, Novo Nordisk) in people with T2D was established in the Liraglutide Effect and Action in Diabetes: Evaluation of CV Outcome Results (LEADER) study, showing a 13% reduction in major CV events over an average of 3.8 years [44]

Figure 29: Photograph of Professor Catherine rskov, credit: rskov
